Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa

Thrombosis Research

Volumn 128, Issue 2, 2011, Pages 191-195

  Karpf, Ditte M ^a   Sørensen, Brit B ^a   Hermit, Mette B ^a   Holmberg, Heidi L ^a   Tranholm, Mikael ^a   Bysted, Britta V ^a   Groth, Andreas V ^a   Bjørn, Søren E ^a   Stennicke, Henning R ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Clearance; Half life; PEGylation; Pharmacokinetics; Preclinical; rFVIIa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; FEMALE; HEMOPHILIA A; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; FACTOR VIIA; FEMALE; GLYCOSYLATION; HALF-LIFE; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; MICE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SWINE; SWINE, MINIATURE; TAIL;

EID: 79960392729     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.02.018     Document Type: Article

References (29)

1. E. Berntorp, J. Astermark, S. Bjorkman, V.S. Blanchette, K. Fischer, and P.L. Giangrande Consensus perspectives on prophylactic therapy for haemophilia: summary statement Haemophilia 9 Suppl 1 2003 1 4 (Pubitemid 36622042)
2. V.S. Blanchette, M. Manco-Johnson, E. Santagostino, and R. Ljung Optimizing factor prophylaxis for the haemophilia population: where do we stand? Haemophilia 10 Suppl 4 2004 97 104 (Pubitemid 40045427)
3. M.J. Manco-Johnson, T.C. Abshire, A.D. Shapiro, B. Riske, M.R. Hacker, and R. Kilcoyne Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia N Engl J Med 357 2007 535 544 (Pubitemid 47236278)
4. A. Srivastava Dose and response in haemophilia-optimization of factor replacement therapy Br J Haematol 127 2004 12 25 (Pubitemid 39331102)
5. B.A. Konkle, L.S. Ebbesen, E. Erhardtsen, R.P. Bianco, T. Lissitchkov, and L. Rusen Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors J Thromb Haemost 5 2007 1904 1913 (Pubitemid 47288949)
6. M. Morfini, G. Auerswald, R.A. Kobelt, G.F. Rivolta, J. Rodriguez-Martorell, and F.A. Scaraggi Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres Haemophilia 13 2007 502 507 (Pubitemid 47337989)
7. E. Erhardtsen Pharmacokinetics of recombinant activated factor VII (rFVIIa) Semin Thromb Hemost 26 2000 385 391
8. E. Berntorp, and S. Bjorkman The pharmacokinetics of clotting factor therapy Haemophilia 9 2003 353 359 (Pubitemid 36874381)
9. C.S. Fishburn The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics J Pharm Sci 97 2008 4167 4183
10. R. Mehvar Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation J Pharm Pharm Sci 3 2000 125 136
11. H.R. Stennicke, H. Ostergaard, R.J. Bayer, M.S. Kalo, K. Kinealy, and P.K. Holm Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives Thromb Haemost 100 2008 920 928
12. J.H. Morrissey, B.G. Macik, P.F. Neuenschwander, and P.C. Comp Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation Blood 81 1993 734 744 (Pubitemid 23040866)
13. P. Wildgoose, Y. Nemerson, L.L. Hansen, F.E. Nielsen, S. Glazer, and U. Hedner Measurement of basal levels of factor VIIa in hemophilia A and B patients Blood 80 1992 25 28
14. H.L. Holmberg, B. Lauritzen, M. Tranholm, and M. Ezban Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice J Thromb Haemost 7 2009 1517 1522
15. L. Bi, A.M. Lawler, S.E. Antonarakis, K.A. High, J.D. Gearhart, and H.H. Kazazian Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A Nat Genet 10 1995 119 121
16. L. Bi, R. Sarkar, T. Naas, A.M. Lawler, J. Pain, and S.L. Shumaker Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies Blood 88 1996 3446 3450 (Pubitemid 26365578)
17. S.X. Peng, B.A. Rockafellow, T.M. Skedzielewski, N.D. Huebert, and W. Hageman Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice J Pharm Sci 98 2009 1877 1884
18. M. Hoffman, D.M. Monroe, and H.R. Roberts Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII Blood Coagul Fibrinolysis 9 1998 S61 S65
19. D.M. Monroe, M. Hoffman, J.A. Oliver, and H.R. Roberts Platelet activity of high-dose factor VIIa is independent of tissue factor Br J Haematol 99 1997 542 547 (Pubitemid 27519853)
20. S. Ghosh, P. Sen, U.R. Pendurthi, and L.V. Rao Activity and regulation of glycoPEGylated factor VIIa analogs J Thromb Haemost 6 2008 1525 1533
21. E.T. Parker, and P. Lollar A quantitative measure of the efficacy of factor VIII in hemophilia A mice Thromb Haemost 89 Mar 2003 480 485 (Pubitemid 36329238)
22. M. Tranholm, K. Kristensen, A.T. Kristensen, C. Pyke, R. Rojkjaer, and E. Persson Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A Blood 102 2003 3615 3620 (Pubitemid 37409379)
23. P.B. Johansen, S.E. Bjorn, H. Agerso, I. Thorup, M.B. Hermit, and B.B. Sorensen Prolonged effect of GlycoPEGylated rFVIIa (40 k-PEG-rFVIIa) in rabbits correlates to activity in plasma Thromb Haemost 104 2010 157 164
24. T. Klitgaard, and T.G. Nielsen Overview of the human pharmacokinetics of recombinant activated factor VII Br J Clin Pharmacol 65 2008 3 11 (Pubitemid 350265177)
25. T. Yamaoka Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice J Pharm Sci 83 1994 601 606 (Pubitemid 24222392)
26. S.J. Bell, C.M. Fam, E.A. Chlipala, S.J. Carlson, J.I. Lee, and M.S. Rosendahl Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic Bioconjug Chem 19 2008 299 305 (Pubitemid 351213862)
27. J. Mordenti Pharmacokinetics and interspecies scaling of recombinant human factor VIII Toxicol Appl Pharmacol 136 1996 75
28. J. Mordenti Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins Pharm Res 8 1991 1351
29. J. Moss, A. Rosholm, and A. Laurén Safety and pharmacokinetics of a long-acting glycoPEGylated rFVIIa derivative: a first human dose trial in healthy subjects J Thromb Haemost 7 suppl 2 2009 Abstract number OC-WE-055